Compare QTTB & AMCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTTB | AMCX |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.1M | 411.2M |
| IPO Year | 2018 | 2011 |
| Metric | QTTB | AMCX |
|---|---|---|
| Price | $15.68 | $11.20 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.00 | $7.33 |
| AVG Volume (30 Days) | ★ 2.0M | 483.5K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | 132.55 |
| EPS | ★ N/A | N/A |
| Revenue | $53,737,000.00 | ★ $2,311,801,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $5.64 |
| 52 Week High | $23.57 | $11.13 |
| Indicator | QTTB | AMCX |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 64.68 |
| Support Level | $14.13 | $9.31 |
| Resistance Level | $23.57 | N/A |
| Average True Range (ATR) | 1.63 | 0.59 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 13.67 | 97.59 |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.